New Clinical and Real-World Data for Genentech’s Vabysmo at ASRS Reveal Improved Outcomes for People With Two Leading Causes of Vision Loss

Genentech, a member of the Roche Group, announced today that data from its ophthalmology portfolio will be featured in 25 abstracts at the American Society of Retina Specialists (ASRS) Annual Meeting (ASRS). ) 2023, taking place from July 28 to August 1 in Seattle, WA. The data reinforce the depth of clinical and real-world evidence supporting the use of Vabysmo, the first and only ocular dual-specific antibody, for the treatment of macular degeneration. Age- or neovascularization (AMD) and diabetic macular edema (DME).
“The clinical and real-world data at ASRS reinforce the improvement in outcomes brought by Vabysmo in two leading causes of vision loss, particularly new analyses suggesting that Vabysmo is associated with less vision-impacting fibrosis than aflibercept,”
“By improving disease control while offering a potentially less frequent treatment regimen, Vabysmo may help people spend less time managing their condition.”
Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development.
Vabysmo is currently approved in more than 70 countries for the treatment of AMD and wet DME, with more than one million doses distributed worldwide. Wet AMD and DME are the two leading causes of vision loss, together affecting more than two million people in the United States and 40 million worldwide.
Next Post

Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

Genmab A/S today announced that the European Medicines Agency (EMA) Committee for Human Medicinal Products (CHMP) has adopted a positive opinion proposing a conditional marketing authorization for ecoritamab as monotherapy in the treatment of adult patients with relapsed or refractory dual- or multiple-lineage systemic B-cell lymphoma (DLBCL). The European Commission’s […]